Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis
Program death-1 inhibitors, a class of immune-checkpoint inhibitors, are now the standard of care in a variety of cancer settings, including cutaneous malignancies, such as melanomas, Merkel cell, and cutaneous squamous cell carcinomas (cSCCs). The clinical trials that led to the approval of the pro...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-03-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/528414 |
| _version_ | 1797855929516949504 |
|---|---|
| author | Stacy Grace de Lima Martin D. Hyrcza Jose Gerard Monzon |
| author_facet | Stacy Grace de Lima Martin D. Hyrcza Jose Gerard Monzon |
| author_sort | Stacy Grace de Lima |
| collection | DOAJ |
| description | Program death-1 inhibitors, a class of immune-checkpoint inhibitors, are now the standard of care in a variety of cancer settings, including cutaneous malignancies, such as melanomas, Merkel cell, and cutaneous squamous cell carcinomas (cSCCs). The clinical trials that led to the approval of the programmed death-1 inhibitor cemiplimab-rwlc (Libtayo®) for use in advanced cSCC excluded patients with autoimmune disease and those that required systemic immunosuppressive treatments, or had undergone solid-organ transplantation. Also, to be eligible, patients had to have adequate organ function. Here, we present the first report of a patient that has been successfully treated with cemiplimab for locally advanced cSCC while simultaneously on dialysis for treatment of renal failure following renal transplant. |
| first_indexed | 2024-04-09T20:32:03Z |
| format | Article |
| id | doaj.art-30e6268a1c734480b05ce694f03c8fcc |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-04-09T20:32:03Z |
| publishDate | 2023-03-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-30e6268a1c734480b05ce694f03c8fcc2023-03-30T15:14:19ZengKarger PublishersCase Reports in Oncology1662-65752023-03-0116113714210.1159/000528414528414Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on DialysisStacy Grace de Lima0Martin D. Hyrcza1Jose Gerard Monzon2Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaDepartment of Pathology and Laboratory Medicine and Arnie Charbonneau Cancer Center, University of Calgary, Calgary, AB, CanadaTom Baker Cancer Centre, Calgary, AB, CanadaProgram death-1 inhibitors, a class of immune-checkpoint inhibitors, are now the standard of care in a variety of cancer settings, including cutaneous malignancies, such as melanomas, Merkel cell, and cutaneous squamous cell carcinomas (cSCCs). The clinical trials that led to the approval of the programmed death-1 inhibitor cemiplimab-rwlc (Libtayo®) for use in advanced cSCC excluded patients with autoimmune disease and those that required systemic immunosuppressive treatments, or had undergone solid-organ transplantation. Also, to be eligible, patients had to have adequate organ function. Here, we present the first report of a patient that has been successfully treated with cemiplimab for locally advanced cSCC while simultaneously on dialysis for treatment of renal failure following renal transplant.https://www.karger.com/Article/FullText/528414immunotherapydialysissquamous cell carcinomacase report |
| spellingShingle | Stacy Grace de Lima Martin D. Hyrcza Jose Gerard Monzon Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis Case Reports in Oncology immunotherapy dialysis squamous cell carcinoma case report |
| title | Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis |
| title_full | Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis |
| title_fullStr | Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis |
| title_full_unstemmed | Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis |
| title_short | Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis |
| title_sort | treatment of unresectable cutaneous squamous cell carcinoma with cemiplimab in a patient on dialysis |
| topic | immunotherapy dialysis squamous cell carcinoma case report |
| url | https://www.karger.com/Article/FullText/528414 |
| work_keys_str_mv | AT stacygracedelima treatmentofunresectablecutaneoussquamouscellcarcinomawithcemiplimabinapatientondialysis AT martindhyrcza treatmentofunresectablecutaneoussquamouscellcarcinomawithcemiplimabinapatientondialysis AT josegerardmonzon treatmentofunresectablecutaneoussquamouscellcarcinomawithcemiplimabinapatientondialysis |